Orphazyme A/S US IPO
The Danish biotech company Orphazyme A/S listed on Nasdaq Copenhagen A/S has completed a global offering, which included an initial public offering of American Depositary Shares on the Nasdaq Global Market in the United States and an European private placement of ordinary shares. Orphazyme A/S has raised DKK 535 million as part of the global offering.
The purpose of the global offering is to access the United States' capital markets and raise funds to support Orphazyme A/S's current business plan.
Plesner assisted BofA Securities, Inc., Danske Bank A/S, Cowen and Company, LLC, and Guggenheim Securities LLC with the transaction.
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases.
Orphazyme is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases.
Arimoclomol, Orphazyme’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM) and Gaucher disease.
Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland.